This review synthesizes the basic science and clinical evidence on extracellular matrix (ECM) scaffolds used to augment or bridge rotator cuff repairs. It examines host immune response, remodeling, mechanical and suture retention properties, and the mixed clinical outcomes of commercially available devices. The authors also propose a 6-grade rotator cuff pathology system to frame when scaffolds may be indicated.
The core teaching point: not all ECM scaffolds behave alike, and the host response is driven largely by processing. Remember the rule — cross-linking biases the host toward M1 proinflammatory, destructive remodeling, while non-cross-linked, rapidly resorbed material (SIS) favors constructive M2 remodeling.
But biology does not equal clinical benefit. Despite favorable animal data, the only RCT (Iannotti, porcine SIS) showed no benefit and possibly worse outcomes, plus a real rate of sterile inflammatory reactions from residual porcine DNA. Human dermis (GraftJacket) data look better but come only from uncontrolled case series, so efficacy is not established.
For exams and the OR: animal-derived ECM is FDA-cleared only for augmentation, not bridging. Small-to-medium acute tears heal ~90% and do not need a scaffold. Reserve consideration for large-to-massive tears where retear risk is high.
This review synthesizes the basic science and clinical evidence on extracellular matrix (ECM) scaffolds used to augment or bridge rotator cuff repairs. It examines host immune response, remodeling, mechanical and suture retention properties, and the mixed clinical outcomes of commercially available devices. The authors also propose a 6-grade rotator cuff pathology system to frame when scaffolds may be indicated.
The core teaching point: not all ECM scaffolds behave alike, and the host response is driven largely by processing. Remember the rule — cross-linking biases the host toward M1 proinflammatory, destructive remodeling, while non-cross-linked, rapidly resorbed material (SIS) favors constructive M2 remodeling.
But biology does not equal clinical benefit. Despite favorable animal data, the only RCT (Iannotti, porcine SIS) showed no benefit and possibly worse outcomes, plus a real rate of sterile inflammatory reactions from residual porcine DNA. Human dermis (GraftJacket) data look better but come only from uncontrolled case series, so efficacy is not established.
For exams and the OR: animal-derived ECM is FDA-cleared only for augmentation, not bridging. Small-to-medium acute tears heal ~90% and do not need a scaffold. Reserve consideration for large-to-massive tears where retear risk is high.